Low phosphatemia in extremely low birth weight neonates: A risk factor for hyperglycemia?

Lélia Dreyfus1, Céline Julie Fischer Fumeaux2, Laurent Remontet3

  • 1Hospices Civils de Lyon, Service de Réanimation Néonatale et Néonatologie, Hôpital Femme Mère Enfant, Bron, France.

Insights

Low phosphate levels in extremely low birth weight (ELBW) neonates are linked to a higher risk of hyperglycemia. This finding suggests that managing phosphate may help prevent glucose intolerance in these vulnerable infants.

Area of Science:

  • Neonatal Medicine
  • Pediatric Endocrinology
  • Metabolic Disorders

Background:

  • Hyperglycemia affects over half of extremely low birth weight (ELBW) neonates, increasing morbidity and mortality.
  • Hypophosphatemia is a common metabolic issue in ELBW infants.
  • Existing research suggests a link between hypophosphatemia and glucose intolerance.

Purpose of the Study:

  • To investigate the association between low phosphate levels (hypophosphatemia) and hyperglycemia in ELBW neonates.
  • To determine if phosphatemia is a predictor of hyperglycemia in this population.

Main Methods:

  • An observational study of 148 ELBW infants admitted to a tertiary neonatal care center.
  • Routine measurement of phosphatemia and glycemia during parenteral nutrition.
  • Statistical analysis using a joint model to assess the relationship between phosphate and hyperglycemia.

Main Results:

  • 57% of ELBW infants in the study experienced hyperglycemia.
  • A decrease in phosphate levels was significantly associated with an increased hazard of hyperglycemia.
  • Each 0.41 mmol/L decrease in phosphate level multiplied the hazard of hyperglycemia by 3 (at the same time) and by 3.85 (the day before).

Conclusions:

  • This study provides the first evidence suggesting a link between hypophosphatemia and hyperglycemia in ELBW neonates.
  • Further research is needed to confirm if phosphate level management can prevent hyperglycemia in ELBW infants.
Abstract

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.4K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
482
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
337
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
750
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K